Release – Comtech Telecommunications Corp. Announces Results for its Third Quarter of Fiscal 2022 and Updates Fiscal 2022 Financial Targets



Comtech Telecommunications Corp. Announces Results for its Third Quarter of Fiscal 2022 and Updates Fiscal 2022 Financial Targets

Research, News, and Market Data on Comtech Telecommunications

MELVILLE, N.Y.–(BUSINESS WIRE)–Jun. 9, 2022–

June 9, 2022–Comtech Telecommunications Corp. (NASDAQ: CMTL), a leading global provider of next-generation 911 emergency systems and secure wireless communications technologies, today announced its third quarter fiscal 2022 financial results and updated its fiscal 2022 financial targets in a letter to shareholders which is now posted to the Investor Relations section of Comtech’s website.

Investors are invited to access the third quarter fiscal 2022 shareholder letter at its web site at investor.comtech.com. A copy of the letter will also be filed with the Securities and Exchange Commission in a Form 8-K.

Comtech also intends to host a previously scheduled earnings conference call at 5:00PM ET today that is intended to be briefer but provide more time for questions and discussion. Individuals can access the conference call by dialing (800) 895-3361 (domestic) or (785) 424-1062 (international) and using the conference I.D. of “Comtech.” A replay of the conference call will be available for seven days by dialing (877) 856-8965 or (402) 220-1609. A live webcast of the call is also available at investor.comtech.com.

Comtech Telecommunications Corp. is a leading global provider of next-generation 911 emergency systems and secure wireless communications technologies to commercial and government customers around the world. Headquartered in Melville, New York and with a passion for customer success, Comtech designs, produces and markets advanced and secure wireless solutions. For more information, please visit www.comtech.com.

Certain information in this press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties. Actual results could differ materially from such forward-looking information. The Company’s Securities and Exchange Commission filings identify many such risks and uncertainties. Any forward-looking information in this press release is qualified in its entirety by the risks and uncertainties described in such Securities and Exchange Commission filings.

PCMTL

View source version on 
businesswire.comhttps://www.businesswire.com/news/home/20220609005896/en/

Investor Relations
Robert Samuels
631-962-7105

robert.samuels@comtech.com

Source: Comtech Telecommunications Corp.


New EV Charging Station Proposal by White House


Image Credit: RoK (Flickr)


White House Plans to Make EV Ownership Easier is of Interest to Investors

The dream of care-free travel, at low cost and low environmental impact, in an electric vehicle (EV) just got a little closer to reality. The White House has announced (June 6) guidelines intended to standardize charging stations while using tax dollars to make these stations more available and reliable. The proposal outlines what new charging stations need to have to qualify for access to the billions being spent on infrastructure. The initial intent is to help create 500,000 charging stations along major arteries in 5 years at the cost of $5 billion. The standards do not match the current largest charging network and standards produced by Tesla, Inc. (TSLA).

About Biden’s Proposal

The White House aims to standardize the chargers by making sure that federally subsidized outlets all offer similar payment systems, charging speeds, pricing information, and functionality. The idea, according to the Department of Transportation (DOT), is to ensure ease of charging regardless of the brand of car, state, or roadway.

Under the rules, charging stations will not be allowed to require membership for use. The White House also laid out standards for how charging stations should be maintained over time; the intent is to reduce the persistent problem of broken chargers.

One of the biggest charging providers currently in the US does match the criteria under the new standards. Tesla Motors chargers with proprietary connections do not qualify, it isn’t clear if the company will succumb to the Washington standard or continue with its proprietary outlets.

The push forward of this plan for 500,000 charging stations is worth the attention of investors in both materials and car manufacturers. The increasing adoption of electric infrastructure and batteries could provide significant growth opportunity for investors in EVs, and producers of copper, stainless steel, aluminum, nickel, chrome, cobalt, and lithium, as well as manufacturers of polycarbonates, elastomers, and thermoplastics polyurethanes used for critical manufacturing components of EV charging stations, such as enclosures, cables, connectors, cable insulation and jacketing, and flexible conduits.

Take Away

Federal subsidies were announced that would be made available to build out the EV charging station network to provide a more attractive and cost-effective experience to help induce more purchases of electric vehicles.

The $5 billion being made available requires uniformity to ensure a similar experience and not provide a preference to one manufacturer over another.

The enormous amounts being spent by governmental agencies for this project should regain the attention of investors in metals and miners. Providers of other materials used in the construction of charging stations that could likely win a government contract are also worth analyzing.

Paul Hoffman

Managing Editor, Channelchek


Suggested Reading



Lithium Inflation and Availability Concerns Elon Musk



Enough US Produced Lithium to Exceed Today’s Demand





The Appeal of EVs with Bidirectional Charging



Copper Facing an Onslaught of Demand

Source

https://www.whitehouse.gov/briefing-room/statements-releases/2022/06/09/fact-sheet-biden-harris-administration-proposes-new-standards-for-national-electric-vehicle-charging-network/

https://driveelectric.gov/resources/

https://www.meticulousresearch.com/product/ev-charging-station-raw-materials-market-5200

https://www.fhwa.dot.gov/environment/alternative_fuel_corridors/resources/nprm_evcharging_unofficial.pdf

Stay up to date. Follow us:

 

Household Finances in Great Shape to Weather the Better than Forecast Economy


Image Credit: Ken Teegardin


Belt Tightening Not Necessary as Top Strategist Sees No Long-Term Economic Malaise

The possible long-term economic decline that the market fears may be unwarranted, says a top strategist at JPMorgan Chase. Most importantly, he backs his case up with compelling data. This comes just before the economy has 21 days to prove it is not in a recession. As a reminder, the textbook definition of a recession is two consecutive quarters of economic growth as measured by GDP. The GDP growth rate for the first quarter of 2022 is reported to have shrunk by 1.5%. As we approach the end of the second quarter, the economy seems to continue to fade. Since investors, workers, and business owners all have a stake in the economy’s overall health, they may take comfort in the projection of Mike Bell, a global market strategist at JPMorgan Asset Management, on the future of the U.S. economy.

What He Said with Context

“Our base case is not that we get a recession in the US in the near term,” Mike Bell, the global market strategist at JPMAM said at a conference on Wednesday. Bell explained the key economic ingredient that reduces the chance of prolonged decline in the US economy is that Americans are harboring higher than usual amounts in savings. This level of savings grew during the pandemic-economy. The post-pandemic economy, Bell believes, will also benefit as this will help prevent price shocks with high inflation.

The global market strategist backed up his argument, using a Chase Bank homegrown chart showing deposits. JPMorgan Chase is the world’s sixth-largest bank, and the largest in the U.S.

Consumer Savings Increase

Internal JPMorgan data demonstrates Americans have built up a cushion of savings. The statistics show that households have double the amount of savings they had at the start of the pandemic (using February 2020 as base). Discussing the above chart, Bell pointed out, “See in the U.S. how much the stimulus checks boosted savings, particularly for the lower income group,” and continued, “Part of the reason we had a lot of booming economic growth and inflation over the last year was that some of that got spent. But they’re still sat, on average, on somewhere like double the amount of savings they had at the beginning of the pandemic.” He believes the consumer will continue to consume and not retrench to a level tha causes severe economic impact.

However, Bell said there’s still a chance the Federal Reserve raises interest rates so far it would trigger a recession. And he said central bankers and finance ministers face a trade-off. If there’s no recession, then inflation is likely to stay above the central banks’ 2% target for a lengthy period.

Take Away

Economics is not an exact science. Most economists are accused of saying, “on the one hand this, on the other hand, that…” There are so many inputs, that predicting a month out is far more difficult than predicting the weather a month out. And no one expects any weatherman to be correct.

The global strategist at JPMorgan Chase is using insight that is different than those clamoring about inflation, a tight job market, or interest rates. Investors may benefit from understanding the more positive data and crossing that with everything else they are digesting. In this case, the thought is that the consumer won’t retrench because they do not have to. Their savings is above previous periods.

Paul Hoffman

Managing Editor, Channelchek

Suggested Content



Why Good Economic Numbers Can Cause a Selloff



How PPI Impacts CPI Numbers




Michael Burry Uses Burgernomic’s logic to Evaluate the US Dollar



Inflation Sticker Shock to be on Powell Says President


Sources

https://www.doughroller.net/banking/largest-banks-in-the-world/

https://markets.businessinsider.com/news/stocks/us-recession-unlikely-jpmorgan-prediction-consumer-savings-stimulus-economy-slowdown-2022-6

https://am.jpmorgan.com/us/en/asset-management/adv/insights/market-insights/market-updates/notes-on-the-week-ahead/

Stay up to date. Follow us:

 

Release – Shareholders Approve All Resolutions at Aurania’s Annual and Special Meeting



Shareholders Approve All Resolutions at Aurania’s Annual and Special Meeting

Research, News, and Market Data on Aurania Resources

Toronto, Ontario, June 9, 2022 – Aurania Resources Ltd. (TSXV:
ARU) (OTCQB: AUIAF) (Frankfurt: 20Q) (“Aurania” or the “Company”)
 is pleased to announce that its shareholders have approved all resolutions at the Company’s Annual and Special Meeting (the “Meeting”) which was held on June 8, 2022.

At the Meeting, shareholders approved the financial statements for the year-ended December 31, 2021, and the report of the auditors thereon, the appointment of auditors, election of directors and the Company’s incentive stock option plan for the upcoming year.  Details of these matters are disclosed in the Management Information Circular for the Meeting dated April 28, 2022, and posted under the Company’s profile on www.sedar.com and on the Company’s corporate website 
http://www.aurania.com/investors/annual-general-meeting/.

The formal part of the Meeting was followed by a presentation and a brief question-and-answer period.  The webcast replay is available now and can be accessed until September 8, 2022, via the original webcast link. The audio-only replay will be available in the coming days and will be posted on Aurania’s website.  Forward-looking statements were made during the activities update and question-and-answer period.

About Aurania

Aurania is a mineral exploration company engaged in the identification, evaluation, acquisition and exploration of mineral property interests, with a focus on precious metals and copper in South America.  Its flagship asset, The Lost Cities – Cutucu Project, is located in the Jurassic Metallogenic Belt in the eastern foothills of the Andes mountain range of southeastern Ecuador.

Information on Aurania and technical reports are available at www.aurania.com and www.sedar.com, as well as on Facebook at https://www.facebook.com/auranialtd/, Twitter at  
https://twitter.com/auranialtd, and LinkedIn at https://www.linkedin.com/company/aurania-resources-ltd-.

For further information, please contact:

Carolyn Muir

VP Investor Relations

Aurania Resources Ltd.

(416) 367-3200

carolyn.muir@aurania.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

Forward-Looking Statements

This news release may contain forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurania. Forward-looking statements include estimates and statements that describe Aurania’s future plans, objectives or goals, including words to the effect that Aurania or its management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to Aurania, Aurania provides no assurance that actual results will meet management’s expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to Aurania’s objectives, goals or future plans, statements, exploration results, potential mineralization, the corporation’s portfolio, treasury, management team and enhanced capital markets profile, the estimation of mineral resources, exploration, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, failure to identify mineral resources, failure to convert estimated mineral resources to reserves, the inability to complete a feasibility study which recommends a production decision, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, regulatory, environmental or other project approvals, political risks, inability to fulfill the duty to accommodate indigenous peoples, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects, capital and operating costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry, the effects of COVID-19 on the business of the Company including but not limited to the effects of COVID-19 on the price of commodities, capital market conditions, restrictions on labour and international travel and supply chains, and those risks set out in Aurania’s public documents filed on SEDAR. Although Aurania believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Aurania disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.


Release – Chakana Copper Provides Exploration Update and Resumes Drilling at the Soledad Project, Peru



Chakana Copper Provides Exploration Update and Resumes Drilling at the Soledad Project, Peru

Research, News, and Market Data on Chakana Copper

Soledad Project Highlights Include:

  • Drilling campaign will test
    thirteen new targets on the north side of the Soledad project.
  • The priority targets were
    selected from an inventory of 154 total targets defined after integrating
    results from recently completed geophysical surveys.
  • Permitting on the south
    side of the project is advancing and will allow testing of additional high
    priority targets once approved.

Vancouver, British Columbia–(Newsfile Corp. – June 9, 2022) – Chakana Copper Corp. (TSXV: PERU) (OTCQB: CHKKF)
(FSE: 1ZX) 
(the Company or Chakana“), is pleased to confirm that drilling will start June 15, 2022 to test thirteen new targets not previously drilled on the north side of the project. These thirteen targets were selected from a total of 154 targets identified on the project that were prioritized during an in-house technical workshop incorporating recently acquired Offset IP survey results. The objective of the drill program is to test the exploration potential of numerous additional targets beyond the targets that have been drilled leading to the initial resource estimate for the project (see news release dated January 11, 2022).

“For 2022, our goal is to test
some of the best targets outside the current resource area to better understand
the upside potential of the Soledad project. Although we have numerous targets
defined on the project, these targets rank highly based on the multiple
datasets derived as a result of detailed mapping, rock and soil geochemistry,
geophysical surveys, detailed modeling of several well-mineralized targets, and
an improved understanding of the structural controls on the Soledad mineral
system,” 
stated President and CEO David Kelley.

Exploration Update and 2022 Drill
Program

A targeting workshop was recently held to review and update drill targets for the Soledad project. Since the original targeting workshop was held in 2019, several new data sets have been acquired over the entire 12 square kilometer area of the prospective Soledad mineral system. New data sets incorporated into the targeting include 1) detailed ground magnetics, 2) gradient array induced polarization, 3) offset (3D) induced polarization, 4) detailed mapping, and 5) hyperspectral alteration mineralogy studies.

Targets are categorized as breccias, vein-breccias, mineralized intrusions, and high sulfidation alteration zones, representing a continuum of mineralization styles related to an intrusive-driven mineral system that underlies the Soledad project (Figure 1). Drilling will begin on June 15, 2022 with one drill rig to test thirteen targets with approximately 3,000m of drill core with one or two holes in each target. Once these targets have been drilled, a decision will be made regarding both additional target testing and follow-up drilling.

The principal target areas for the next round of drilling on the north side of the project are 1) Cima Blanca, 2) Bx 4 cluster, 3) Faro, 4) Western Breccias, 5) Paloma Trend, and 6) Paloma-Huancarama megabreccia target (Figure 1). A number of targets exist in the Paloma Trend and Paloma-Huancarama area defined by outcropping tourmaline breccias, and Gradient Array IP and Offset IP metal factor anomalies (Figure 2).

Three principal target areas exist on the south side of the project: 1) Compañero breccia complex, 2) Mega-gold anomaly, and 3) La Joya (Figure 1). The Compañero breccias are similar to the mineralized breccia pipes on the north side of the project with strongly enriched gold in surface rock channel samples (see news release dated July 16, 2018). The Mega-gold target is defined by a large soil anomaly strongly anomalous in gold-molybdenum-tin, in part overlying a poorly exposed, phylically-altered granodiorite intrusion. The La Joya target area shows evidence of high sulfidation advanced argillic alteration with vuggy silica, alunite, dickite, zunyite, diaspore, and pyrophyllite.

About Chakana Copper

Chakana Copper Corp is a Canadian-based minerals exploration company that is currently advancing the Soledad Project located in the Ancash region of Peru, a highly favorable mining jurisdiction with supportive communities. The Soledad Project is notable for the high-grade copper-gold-silver mineralization that is hosted in tourmaline breccia pipes. An initial inferred resource estimate for seven breccia pipes was announced in Q1 2022 (see news release dated February 23, 2022), with 6.73 Mt containing 191,000 ounces of gold, 11.7 million ounces of silver, and 130 million pounds of copper. In addition, extensive multidisciplinary exploration has defined 154 exploration targets, 18 of which have been tested to date (12%), confirming that Soledad is a large, well-endowed mineral system with strong exploration upside. Chakana’s investors are uniquely positioned as the Soledad Project provides exposure to copper and precious metals. For more information on the Soledad project, please visit the website at www.chakanacopper.com.

Results of an initial resource estimate and additional information concerning the Project, including a technical report prepared in accordance with National Instrument 43-101, are available on Chakana’s profile at 
www.sedar.com.

Qualified Person
David Kelley, an officer, and a director of Chakana, and a Qualified Person as defined by NI 43-101, reviewed and approved the technical information in this news release.

ON BEHALF OF THE BOARD
(signed) “David Kelley
David Kelley
President and CEO

For further information contact:
Joanne Jobin, Investor Relations Officer
Phone: 647 964 0292
Email: 
jjobin@chakanacopper.com

Neither TSX
Venture Exchange nor its Regulation Services Provider (as that term is defined
in the policies of the Exchange) accepts responsibility for the adequacy or
accuracy of this release.

Forward-looking Statement Advisory

This release may contain
forward-looking statements. Forward-looking statements involve known and
unknown risks, uncertainties, and other factors which may cause the actual
results, performance, or achievements of Chakana to be materially different
from any future results, performance, or achievements expressed or implied by
the forward-looking statements. Forward looking statements or information
relates to, among other things, the interpretation of the nature of the
mineralization at the
 Soledad
copper-gold-silver
 project (the
“Project”), the potential to expand the mineralization, and to
develop and grow a resource within the Project, the planning for further
exploration work, the ability to de-risk the potential exploration targets, and
our belief in the potential for mineralization within unexplored parts of the
Project. These forward-looking statements are based on management’s current
expectations and beliefs but given the uncertainties, assumptions and risks,
readers are cautioned not to place undue reliance on such forward- looking
statements or information. The Company disclaims any obligation to update, or
to publicly announce, any such statements, events or developments except as required
by law.

Release – ACCO Brands Corporation Announces Participation in Virtual 2022 East Coast Ideas Conference



ACCO Brands Corporation Announces Participation in Virtual 2022 East Coast Ideas Conference

Research, News, and Market Data on ACCO Brands

06/09/2022

LAKE ZURICH, Ill.–(BUSINESS WIRE)– ACCO Brands Corporation (NYSE: ACCO) today announced that its management will participate in the virtual 2022 East Coast IDEAS Investor Conference. The company’s virtual presentation will be available on June 16 at 8:00 a.m. EDT.

The presentation will be webcast and will be accessible through the Investor Relations section of 
www.accobrands.com, through the conference website 
www.threepartadvisors.com/east-coast, and through the host’s main website www.IDEASconferences.com. The presentation will be archived for 90 days following the event.

About ACCO Brands
Corporation

ACCO Brands Corporation (NYSE: ACCO) is one of the world’s largest designers, marketers and manufacturers of branded academic, consumer and business products. Our widely recognized brands include Artline®, AT-A-GLANCE®, Barrilito®, Derwent®, Esselte®, Five Star®, Foroni®, GBC®, Hilroy®, Kensington®, Leitz®, Mead®, PowerA®, Quartet®, Rapid®, Rexel®, Swingline®, Tilibra®, Wilson Jones® and many others. Our products are sold in more than 100 countries around the world. More information about ACCO Brands, the Home of Great Brands Built by Great People, can be found at www.accobrands.com.

View source version on 
businesswire.comhttps://www.businesswire.com/news/home/20220609005383/en/

Neal Fenwick
Investor Relations
(847) 796-4740

Julie McEwan
Media Relations
(937) 974-8162

Source: ACCO Brands Corporation


Release – Avivagen Announces Successful Completion of Formal Safety and Toxicology Evaluation of Fully Oxidized Beta-Carotene (OxBC)



Avivagen Announces Successful Completion of Formal Safety and Toxicology Evaluation of Fully Oxidized Beta-Carotene (OxBC)

Research, News, and Market Data on Avivagen

Ottawa, ON /Business Wire/ June 9, 2022 /- Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce that it has completed a series of important safety evaluations of fully oxidized beta-carotene (OxBC), the proprietary and critical active ingredient in the company’s highly-regarded OxC-betaTM product line. Results of the Avivagen-initiated toxicology study, conducted following standardized and internationally recognized protocols, provided further evidence of the safety and effectiveness of OxBC and the OxC-betaTM product line for use in human and animal applications.

Based on previously conducted scientific testing, OxBC and Avivagen’s OxC-betaTM product line have achieved self-affirmed GRAS status in the United States and have already secured regulatory approval in a number of other important food and feed markets, including China, Brazil, Philippines, Mexico, Taiwan, New Zealand, Thailand, Vietnam, Australia, and Malaysia.

“Through extensive internal and third-party testing, and both regulatory evaluation and customer trial and adoption of our OxC-beta line around the globe, the safety of OxBC as an active ingredient supporting a wide range of beneficial uses for humans and animals has been shown again and again,” says Kym Anthony, Chief Executive Officer, Avivagen. “Already more than than 35 million livestock animals have seen enhanced health and productivity thanks to the OxBC ingredient, and over 82,000 dogs and 3,300 humans have enjoyed the benefits of OxBC products. As expected, proactively participating in this toxicology assessment has provided further evidence of the safety and effectiveness of our OxC-betaTM line and presents a valuable indicator of the significant commercialization opportunities for our technology as we continue to expand approvals and adoptions in new markets worldwide.”

While there have been zero reports of product-related adverse events from OxBC or OxC-betaTM to date, the present toxicology tests were initiated by Avivagen to further reinforce OxBC’s applicability as a very safe ingredient in a wide range of products and provide further formal evidence to support continued regulatory approval and adoption in both new jurisdictions and product applications. Toxicology testing consisted of three separate studies, all of which are conducted in animals, typically rats. The first test demonstrated that in rats the maximum tolerated single oral dose of OxBC and the LD50 were 5,000 and 30,079 mg/kg body weight, respectively. The second test, a 14-day, repeat-dose acute oral toxicity test demonstrated an initial No Observable Adverse Effect Level (NOAEL) of OxBC of 1,250 mg/kg body weight. In the third and final test, no mortality or morbidity was observed for administration by oral gavage of OxBC up to 1875 mg/kg body weight once daily in male and female Sprague Dawley rats for 90 consecutive days followed by a 28-day recovery period. There were no treatment-related adverse effects on body weight, feed consumption, hematology, coagulation, hormonal, and clinical chemistry parameters and organ weights. No gross pathological abnormalities nor adverse histopathological findings were observed. The NOAEL was determined to be 1875 mg/kg body weight. These findings strongly support the safety of OxBC, especially considering the NOAEL value exceeds by several thousand times the daily level of approximately 0.5 mg/kg body weight of OxBC used in supplementing livestock, canines, felines and humans.

About Avivagen
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.

About OxC-beta™ Technology and OxC-beta™ Livestock
Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about ?-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Brazil, Australia, and Malaysia.

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

Forward Looking Statements
This news release includes
certain forward-looking statements that are based upon the current expectations
of management. Forward-looking statements involve risks and uncertainties
associated with the business of Avivagen Inc. and the environment in which the
business operates. Any statements contained herein that are not statements of
historical facts may be deemed to be forward-looking, including those
identified by the expressions “aim”, “anticipate”, “appear”, “believe”,
“consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”,
“likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”,
“whether”, “will”, “would” and similar expressions.

Statements set out in this news release relating to the future
growth and prospects for Avivagen and the possibility for OxC-beta™ Livestock
to replace antibiotics in livestock feeds as growth promoters are
forward-looking statements. These forward-looking statements are subject to a
number of risks and uncertainties that could cause actual results or events to
differ materially from current expectations. For instance, Avivagen’s products
may not gain market acceptance or regulatory approval in new jurisdictions or
for new applications and may not be widely accepted as a replacement for
antibiotics as growth promoters in livestock feeds due to many factors, many of
which are outside of Avivagen’s control. Readers are referred to the risk
factors associated with the business of Avivagen set out in Avivagen’s most
recent management’s discussion and analysis of financial condition available at
www.SEDAR.com. Except as required by law, Avivagen assumes no obligation to
update the forward-looking statements, or to update the reasons why actual
results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.

For more information:
Avivagen Inc.
Drew Basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Phone: 416-540-0733
E-mail: d.basek@avivagen.com

Kym Anthony

Chief Executive Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Head Office Phone: 613-949-8164

Website: www.avivagen.com
Copyright © 2022 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.


Release – TAAL to Webcast Live at the OTCQX Best 50 Virtual Investors Conference June 16



TAAL to Webcast Live at the OTCQX Best 50 Virtual Investors Conference June 16

Research, News, and Market Data on TAAL

TAAL invites individual and institutional
investor as well as advisors and analysts to attend the interactive
presentation at VirtualInvestorConferences.com

TORONTO, June 9, 2022 /CNW/ – TAAL Distributed Information Technologies Inc. (CSE:TAAL) (FWB:9SQ1) (OTC:TAALF) (“TAAL” or the “Company”), a vertically integrated blockchain infrastructure and service provider for enterprise, announces that CEO Richard Baker will present live at the OTCQX Best 50 Virtual Investors Conference on June 16, 2022 at 11am Eastern Time (details below).  Mr. Baker will also host 1×1 investor meetings through the event.

“TAAL is building the infrastructure needed to power the next generation of the internet,” said CEO, Richard Baker. “We believe in a future beyond block subsidy rewards where revenues are driven by transaction processing and we are on a path to become a major network provider for Web 3.0 and the digital economy; I look forward to sharing this and more with investors at the OTCQX Best 50 conference.”   

Recent Company Highlights

  • Gross revenue from hashing operations was $8.7 million, a $7.8 million increase from $0.9 million compared to the first quarter of the prior year (“Q1 2021”). 
  • Adjusted EBITDA loss of $0.9 million versus a $3.5 million loss in Q1 2021.
  • TAAL processed over 232 million transactions within 9,595 blocks on the BSV network for the quarter, earning almost $0.3 million in additional rewards from transaction processing, representing 3% of total revenue.
  • Future growth secured with deposits for plant and equipment of $34.7 million to expand hashing fleet and a clean energy data center in New Brunswick, Canada.
  • As of March 31, 2022, TAAL had about 23,000 BSV, 600 BCH and 0.5 BTC in coin treasury.

TAAL Investor
Presentation Webcast

DATE: Thursday June 16, 2022

TIME: 11:00am EST
LINK: https://bit.ly/3MB962u

Available for 1×1 meetings: Friday June 17, 2022.

This will be a live, interactive online event where investors are invited to ask the Company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.

It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.

Learn more about the event at www.virtualinvestorconferences.com.

About TAAL Distributed
Information Technologies Inc.

TAAL Distributed Information Technologies Inc. delivers value-added blockchain services, providing professional-grade, highly scalable blockchain infrastructure and transactional platforms to support businesses building solutions and applications upon the BitcoinSV platform, and developing, operating, and managing distributed computing systems for enterprise users.

Visit TAAL online at www.taal.com/investors 

About Virtual Investor
Conferences
®

Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access.  Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

SOURCE Taal Distributed Information Technologies Inc.

For further information: Media and Investor Contact: TAAL, Richard Baker, Chief Executive Officer, Office: (437) 826-8889, Richard.Baker@taal.com; Sophic Capital, Sean Peasgood, President & Chief Executive Officer, Office: (437) 826-8889, Sean@SophicCapital.com


Release – Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models at the 2022 American Transplant Congress



Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models at the 2022 American Transplant Congress

Research, News, and Market Data on Tonix Pharmaceuticals

Research Directed by Faculty of the Center for Transplantation Sciences, Massachusetts General Hospital

CHATHAM, N.J., June 09, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced data from three oral presentations at the 2022 American Transplant Congress (ATC) by faculty at the Center for Transplantation Sciences, Massachusetts General Hospital. The data involve studies of Tonix’s TNX-1500 (Fc-modified anti-CD40L monoclonal antibody) product candidate in development for the prevention of organ transplant rejection. The molecular target of TNX-1500 is CD40-ligand (CD40L), which is also known as CD154. Copies of the presentations are available under Scientific
Presentations
 on the Tonix Pharmaceuticals corporate website at www.tonixpharma.com.

The presentations titled, “Long-Term Rejection Free Renal Allograft Survival with Fc-Modified
Anti-CD154 Antibody Monotherapy in Nonhuman Primates
,” “TNX-1500, an Fc-modified Anti-CD154 Antibody, Prolongs Nonhuman Primate
Cardiac Allograft Survival
,” and “Novel Targetable Pathways in Costimulation Pathway Blockade” include data demonstrating that TNX-1500 showed activity in preventing organ rejection and was well tolerated in non-human primates. Blockade of CD40L with TNX-1500 monotherapy consistently and safely prevented pathologic alloimmunity in a non-human primate cardiac allograft model without clinical thrombosis.

“There remains a significant need for new treatments with improved activity and tolerability to prevent organ transplant rejection,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “To date, there has not been a humanized anti-CD40L antibody that can effectively prevent transplant rejections with acceptable level of tolerability. TNX-1500 is a third generation anti-CD40L mAb that has been designed by protein engineering to decrease Fc?RII binding and to reduce the potential for thrombosis. The animal studies found that TNX-1500 retains activity to prevent rejection and preserve graft function. We believe TNX-1500 has the potential for treating and preventing organ transplant rejection.”

About Tonix
Pharmaceuticals Holding Corp.
1

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022 and interim data expected in the first quarter of 2023. TNX-102 SL is also being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix expects to initiate a Phase 2 study in Long COVID in the second quarter of 2022. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication that is expected to start a Phase 2 trial in the second quarter of 2022. TNX-1300 has been granted Breakthrough Therapy Designation by the FDA. Finally, TNX-1900 (intranasal potentiated oxytocin), a small molecule in development for chronic migraine, is expected to enter the clinic with a Phase 2 study in the second half of 2022. Tonix’s rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan-Drug Designation by the FDA. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500 which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the second half of 2022. Tonix’s infectious disease pipeline consists of a vaccine in development to prevent smallpox and monkeypox called TNX-801, next-generation vaccines to prevent COVID-19, and a platform to make fully human monoclonal antibodies to treat COVID-19. Tonix’s lead vaccine candidates for COVID-19 are TNX-1840 and TNX-1850, which are live virus vaccines based on Tonix’s recombinant pox live virus vector vaccine platform.

1All of Tonix’s product candidates are investigational new drugs
or biologics and have not been approved for any indication.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward
Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission (the “SEC”) on March 14, 2022, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Contacts

Jessica Morris
(corporate)

Tonix Pharmaceuticals
investor.relations@tonixpharma.com

(862) 799-8599

Olipriya Das,
Ph.D. (media)

Russo Partners
Olipriya.Das@russopartnersllc.com

(646) 942-5588

Peter Vozzo
(investors)

ICR Westwicke
peter.vozzo@westwicke.com

(443) 213-0505


 

Source: Tonix Pharmaceuticals Holding Corp.

Released June
9, 2022


Aurania Resources (AUIAF) – Highlights from the Annual Shareholder Meeting

Thursday, June 09, 2022

Aurania Resources (AUIAF)
Highlights from the Annual Shareholder Meeting

Mark Reichman, Senior Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Annual General Meeting. Aurania hosted the annual meeting of shareholders on June 8 which was accessible via conference call and webcast. Management summarized its immediate exploration strategy, including further prospecting at epithermal gold targets and refining porphyry copper targets in preparation for drilling. Following completion of an environmental impact statement, drilling could commence at copper targets Awacha and Tatasham in the fourth quarter of 2022. While the Kuri Yawi and Kuripan remain high priority gold targets, the discovery of alluvial gold near the location of a historic gold mining center puts attention on other upstream gold targets within Aurania’s concession block. 

Working back to the source. Based on collaborative work with Metron Incorporated, the inferred location of historic gold mining center Logrono de los Caballeros, has been identified. Logrono is one of two, the other being Sevilla de Oro, historic gold mining centers that were thought to be within Aurania’s concession block in Ecuador. While the site is not on Aurania’s concession block, it is downstream and Aurania intends to locate Logrono’s source of alluvial gold….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – Tonix Pharmaceuticals Announces Presentation of Licensed Antiviral Drug Technology at the 4th Symposium of the Canadian Society for Virology



Tonix Pharmaceuticals Announces Presentation of Licensed Antiviral Drug Technology at the 4th Symposium of the Canadian Society for Virology

Research, News, and Market Data on Tonix Pharmaceuticals

Oral Presentation Describes Activity of Wnt/?-Catenin Signaling Pathway Inhibitors Against SARS-CoV-2 in Cell
Culture and in an Animal Model

CHATHAM, N.J., June 08, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Tom Hobman, Ph.D., Professor, Department of Cell Biology, University of Alberta, presented data from his laboratory at The University of Alberta as a keynote presentation at the 4th Symposium of the Canadian Society for Virology held in Edmonton, Alberta, Canada on June 5, 2022. The oral presentation titled, “The
virus-host Interface: A treasure trove of novel antiviral targets,”
 includes research sponsored by Tonix Pharmaceuticals focused on the development and testing of Wnt/?-Catenin signaling pathway inhibitors as broad-spectrum antivirals against SARS-CoV-2 and other emerging viruses. Tonix has previously announced that it exercised an option to license the antiviral technology platform A copy of the presentation is available on the Tonix Pharmaceuticals corporate website at www.tonixpharma.com.

“We are excited by the progress of Professor Hobman and his colleagues at The University of Alberta on the further testing of Wnt/?-Catenin signaling pathway inhibitors as broad-spectrum antivirals,” said Seth Lederman, M.D., President and Chief Executive Officer of Tonix. “Professor Hobman presented data showing that three different Wnt/?-Catenin inhibitor drug candidates decreased lung infection in an animal model of SARS-CoV-2 infection. The set of Wnt/?-Catenin inhibitors tested by Professor Hobman include drugs that have been previously studied in humans for other indications including one drug that is FDA approved. Professor Hobman believes that reducing ?-Catenin levels with Wnt-inhibitor drugs induces peroxisome proliferation and enhances the interferon response. Previously, SARS-CoV-2 was shown to be sensitive to inhibition by interferon2. Professor Hobman reported that Wnt/?-Catenin inhibitor and peroxisome inducing drugs also inhibit Zika virus (ZIKV) and Mayaro (MAYV) virus in cell culture. Tonix is excited to have sponsored Professor Hobman’s research involving Wnt/?-Catenin signaling pathway inhibitors as broad-spectrum antivirals and to have licensed the technology. We look forward to working with Professor Hobman to try to bring one or more of these candidate drugs to clinical testing.”

About Tonix
Pharmaceuticals Holding Corp.
1

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022 and interim data expected in the first quarter of 2023. TNX-102 SL is also being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix expects to initiate a Phase 2 study in Long COVID in the second quarter of 2022. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication that is expected to start a Phase 2 trial in the second quarter of 2022. TNX-1300 has been granted Breakthrough Therapy Designation by the FDA. Finally, TNX-1900 (intranasal potentiated oxytocin), a small molecule in development for chronic migraine, is expected to enter the clinic with a Phase 2 study in the second half of 2022. Tonix’s rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan-Drug Designation by the FDA. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500 which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the second half of 2022. Tonix’s infectious disease pipeline consists of a vaccine in development to prevent smallpox and monkeypox called TNX-801, next-generation vaccines to prevent COVID-19, and a platform to make fully human monoclonal antibodies to treat COVID-19. Tonix’s lead vaccine candidates for COVID-19 are TNX-1840 and TNX-1850, which are live virus vaccines based on Tonix’s recombinant pox live virus vector vaccine platform.

1All of Tonix’s
product candidates are investigational new drugs or biologics and have not been approved
for any indication.

2Lokugamage, K. G. et al., (2020). Journal of
virology, 94 (23), [e01410]. https://doi.org/10.1128/JVI.01410-20

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward
Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission (the “SEC”) on March 14, 2022, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Contacts

Jessica Morris
(corporate)

Tonix Pharmaceuticals
investor.relations@tonixpharma.com

(862) 799-8599

Olipriya Das,
Ph.D. (media)

Russo Partners
Olipriya.Das@russopartnersllc.com

(646) 942-5588

Peter Vozzo
(investors)

ICR Westwicke
peter.vozzo@westwicke.com

(443) 213-0505

 

Source: Tonix Pharmaceuticals Holding Corp.


Artificial Intelligence Language Translation Involves Machines First Hallucinating


Image Credit: Lauren Hinkel (MIT)


Machine Hallucinating to Better Translate Languages

Lauren Hinkel | MIT-IBM Watson AI Lab

As babies, we babble and imitate our way of learning languages. We don’t start off reading raw text, which requires fundamental knowledge and understanding about the world, as well as the advanced ability to interpret and infer descriptions and relationships. Rather, humans begin our language journey slowly, by pointing and interacting with our environment, basing our words and perceiving their meaning through the context of the physical and social world. Eventually, we can craft full sentences to communicate complex ideas.

Similarly, when humans begin learning and translating into another language, the incorporation of other sensory information, like multimedia, paired with the new and unfamiliar words, like flashcards with images, improves language acquisition and retention. Then, with enough practice, humans can accurately translate new, unseen sentences in context without the accompanying media; however, imagining a picture based on the original text helps.

This is the basis of a new machine learning model, called VALHALLA, by researchers from MIT, IBM, and the University of California at San Diego, in which a trained neural network sees a source sentence in one language, hallucinates an image of what it looks like, and then uses both to translate into a target language. The team found that their method demonstrates improved accuracy of machine translation over text-only translation. Further, it provided an additional boost for cases with long sentences, under-resourced languages, and instances where part of the source sentence is inaccessible to the machine translator.

As a core task within the AI field of natural language processing (NLP), machine translation is an “eminently practical technology that’s being used by millions of people every day,” says study co-author Yoon Kim, assistant professor in MIT’s Department of Electrical Engineering and Computer Science with affiliations in the Computer Science and Artificial Intelligence Laboratory (CSAIL) and the MIT-IBM Watson AI Lab. With recent, significant advances in deep learning, “there’s been an interesting development in how one might use non-text information — for example, images, audio, or other grounding information — to tackle practical tasks involving language” says Kim, because “when humans are performing language processing tasks, we’re doing so within a grounded, situated world.” The pairing of hallucinated images and text during inference, the team postulated, imitates that process, providing context for improved performance over current state-of-the-art techniques, which utilize text-only data.

This research will be presented at the IEEE / CVF Computer Vision and Pattern Recognition Conference this month. Kim’s co-authors are UC San Diego graduate student Yi Li and Professor Nuno Vasconcelos, along with research staff members Rameswar Panda, Chun-fu “Richard” Chen, Rogerio Feris, and IBM Director David Cox of IBM Research and the MIT-IBM Watson AI Lab.

 

Learning to Hallucinate
from Images

When we learn new languages and to translate, we’re often provided with examples and practice before venturing out on our own. The same is true for machine-translation systems; however, if images are used during training, these AI methods also require visual aids for testing, limiting their applicability, says Panda.

“In real-world scenarios, you might not have an image with respect to the source sentence. So, our motivation was basically: Instead of using an external image during inference as input, can we use visual hallucination — the ability to imagine visual scenes — to improve machine translation systems?” says Panda.

To do this, the team used an encoder-decoder architecture with two transformers, a type of neural network model that’s suited for sequence-dependent data, like language, that can pay attention key words and semantics of a sentence. One transformer generates a visual hallucination, and the other performs multimodal translation using outputs from the first transformer.

During training, there are two streams of translation: a source sentence and a ground-truth image that is paired with it, and the same source sentence that is visually hallucinated to make a text-image pair. First the ground-truth image and sentence are tokenized into representations that can be handled by transformers; for the case of the sentence, each word is a token. The source sentence is tokenized again, but this time passed through the visual hallucination transformer, outputting a hallucination, a discrete image representation of the sentence. The researchers incorporated an autoregression that compares the ground-truth and hallucinated representations for congruency — e.g., homonyms: a reference to an animal “bat” isn’t hallucinated as a baseball bat. The hallucination transformer then uses the difference between them to optimize its predictions and visual output, making sure the context is consistent.

The two sets of tokens are then simultaneously passed through the multimodal translation transformer, each containing the sentence representation and either the hallucinated or ground-truth image. The tokenized text translation outputs are compared with the goal of being similar to each other and to the target sentence in another language. Any differences are then relayed back to the translation transformer for further optimization.

For testing, the ground-truth image stream drops off, since images likely wouldn’t be available in everyday scenarios.

“To the best of our knowledge, we haven’t seen any work which actually uses a hallucination transformer jointly with a multimodal translation system to improve machine translation performance,” says Panda.

 

Visualizing the
Target Text

To test their method, the team put VALHALLA up against other state-of-the-art multimodal and text-only translation methods. They used public benchmark datasets containing ground-truth images with source sentences, and a dataset for translating text-only news articles. The researchers measured its performance over 13 tasks, ranging from translation on well-resourced languages (like English, German, and French), under-resourced languages (like English to Romanian) and non-English (like Spanish to French). The group also tested varying transformer model sizes, how accuracy changes with the sentence length, and translation under limited textual context, where portions of the text were hidden from the machine translators.

The team observed significant improvements over text-only translation methods, improving data efficiency, and that smaller models performed better than the larger base model. As sentences became longer, VALHALLA’s performance over other methods grew, which the researchers attributed to the addition of more ambiguous words. In cases where part of the sentence was masked, VALHALLA could recover and translate the original text, which the team found surprising.

Further unexpected findings arose: “Where there weren’t as many training [image and] text pairs, [like for under-resourced languages], improvements were more significant, which indicates that grounding in images helps in low-data regimes,” says Kim. “Another thing that was quite surprising to me was this improved performance, even on types of text that aren’t necessarily easily connectable to images. For example, maybe it’s not so surprising if this helps in translating visually salient sentences, like the ‘there is a red car in front of the house.’ [However], even in text-only [news article] domains, the approach was able to improve upon text-only systems.”

While VALHALLA performs well, the researchers note that it does have limitations, requiring pairs of sentences to be annotated with an image, which could make it more expensive to obtain. It also performs better in its ground domain and not the text-only news articles. Moreover, Kim and Panda note, a technique like VALHALLA is still a black box, with the assumption that hallucinated images are providing helpful information, and the team plans to investigate what and how the model is learning in order to validate their methods.

In the future, the team plans to explore other means of improving translation. “Here, we only focus on images, but there are other types of a multimodal information — for example, speech, video or touch, or other sensory modalities,” says Panda. “We believe such multimodal grounding can lead to even more efficient machine translation models, potentially benefiting translation across many low-resource languages spoken in the world.”


Suggested Content



The Most Effective Artificial Intelligence Will Never Exist in the Cloud



How AI is Shaping the Cybersecurity Arms Race





Stock Market Signals Gun Law Tightening Unlikely



Industries that Benefit from Digital Twin Applications

 

Stay up to date. Follow us:

 

Release – Stream Hatchet Launches Stream Hatchet Brands – to Track Earned Media Value from Brand Advertisements In Streaming



Stream Hatchet Launches Stream Hatchet Brands – to Track Earned Media Value from Brand Advertisements In Streaming

Research, News, and Market Data on Engine Gaming & Media

Stream Hatchet Brands enables
the targeted performance measurement of over 2,300 major brands via logo
recognition models and chat analysis on video game streaming platforms

Barcelona, SPAIN – 8 June 2022 – Stream Hatchet, a wholly-owned subsidiary of Engine Gaming and Media, Inc. (“Engine” or the “Company”) (NASDAQ:GAME)(TSXV:GAME), today announced that it has launched Stream Hatchet Brands, a tool and comprehensive database that allows marketers to track earned media value from over 2,300 major brands on video game streaming platforms

Stream Hatchet Brands provides detailed information and curated data sets on the prominence of brand appearances within the top video game streamers, as well as the earned media value generated in each individual frame. This allows marketers to track brand logo impressions related to viewership and brand affinity and present them in dashboards

These dashboards can be filtered into specific categories and industry segments to enhance comparative analysis, and the final data can be processed into a variety of visuals and reports.

Stream Hatchet Brands features three advanced data curation methods:

  • Logo detection with frame by frame
    methodology
     – A bespoke model allows the tracking of brand logos by observing the stream frame by frame. Using this data, internal algorithms generate an earned media value providing a micro-level and highly accurate performance measurement.
  • Logo detection by logo presence
    methodology
     – In addition to tracking brand logos in streaming videos, Stream Hatchet Brands also tracks brand presence on a larger level, allowing brands to benchmark their presence against a broader quantity of live streaming platforms.
  • Chat analysis – Brand mentions are detected by analyzing the complete chat history of all channels, and Stream Hatchet Brands’ advanced methodology tracks specific brand mentions by analyzing the context of the chat to avoid tracking keywords that share the brand name.

More than ever, brands are leveraging gaming influencers and esports events to reach the core gaming audience, which is full of lucrative consumers for various brands,” said Eduard Monsterrat, CEO at Stream Hatchet. “Tracking earned media value on live streams has never been easy, but now with the launch of Stream Hatchet Brands, brand marketers have a simple way of accurately determining the level of brand lift they are generating through sponsorship activations. They can see where their logos appear on stream and how prominent they are compared to competitors, while also tracking brand affinity through audience mentions in chat.

“What makes our products unique”, Montserrat continued, “is our taxonomy and classification methodology. Our data experts spend a copious amount of time properly labelling each individual data point that flows through our reporting offerings, and we never sacrifice quality”.

About Stream Hatchet

Stream Hatchet is the market leader in live-streaming viewership data analytics for the world’s leading video game streaming platforms. Stream Hatchet provides deep insights to leading brands, creator networks, esports leagues, game publishers and other businesses measuring the impact of video game live streaming. Stream Hatchet is a wholly-owned subsidiary of Engine Gaming and Media. For more information, please visit www.streamhatchet.com.

About Engine Gaming and Media,
Inc.

Engine Gaming and Media, Inc. is traded publicly under the ticker symbol (NASDAQ: GAME) (TSX-V: GAME). Engine provides premium social sports and esports gaming experiences, as well as unparalleled data analytics, marketing, advertising, and intellectual property to support its owned and operated direct-to-consumer properties while also providing these services to enable its clients and partners. The company’s subsidiaries include Stream Hatchet, Sideqik, WinView, UMG Gaming, and Frankly Media. For more information, please visit www.enginegaming.com/

Press Kit: 
Media Kit

For further press information, please contact
Amy Ballantyne
Big Games Machine
Email: 
amy@biggamesmachine.com